ArticleInfectious diseases & clinical microbiology2026
Cefiderocol Susceptibility and Carbapenemase Profiles in Carbapenem-Resistant Enterobacterales.
Article in Infectious diseases & clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cefiderocol is a siderophore cephalosporin used as a last resort treatment for infections caused by carbapenem-resistant Enterobacterales (CRE), which pose a threat to public health. This study aimed to determine cefiderocol susceptibility among CRE isolates from the Western Marmara Region of Türkiye and to evaluate the association between cefiderocol susceptibility and carbapenemase type. Materials and Methods: Susceptibility testing of CRE isolates collected from hospitals in Çanakkale and Edirne provinces was performed using the disk diffusion method according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) testing was performed for isolates resistant to cefiderocol or categorized within the area of technical uncertainty (ATU). The presence of Results: A total of 120 CRE isolates were included in the study; 100 of which were collected from Çanakkale and 20 from Edirne. According to EUCAST, cefiderocol susceptibility was 92.5% (n=111), whereas it reached 99% (n=119) under CLSI. The prevalence of KPC, OXA-48, and MBL among the isolates was 48.9%, 31.6%, and 16.3%, respectively. Cefiderocol susceptibility rates among isolates producing KPC, OXA-48, and MBL were 90%, 100%, and 75%, respectively. Conclusion: Isolates producing OXA-48 were more susceptible to cefiderocol than MBL-producing isolates. Cefiderocol may represent an important therapeutic alternative for the treatment of infections caused by CRE in Türkiye. Graphic Abstract: Graphic Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.